Boehringer Ingelheim Testing Copy of Rituxan in Type of Lymphoma

 
(Ref: Bloomberg)
  • Boehringer Ingelheim has started testing a biosimilar version of Roche's Rituxan for non-Hodgkin’s lymphoma, Bloomberg reported Wednesday.
  • Bloomberg Industries analyst Asthika Goonewardene said the company is also recruiting patients in another trial of the drug in rheumatoid arthritis.
  • “Boehringer’s efficient clinical programme may generate the data required to file for regulatory approval in both the US and EU for the two key indications which account for more than 90 percent of Rituxan sales,” Goonewardene added.